Literature DB >> 10811238

Review and management of clozapine side effects.

D D Miller1.   

Abstract

Clozapine has demonstrated superior efficacy in relieving positive and negative symptoms in treatment-resistant schizophrenic patients; unlike other antipsychotics, it causes minimal extrapyramidal side effects (EPS) and has little effect on serum prolactin. Despite these benefits, the use of clozapine has been limited because of infrequent but serious side effects, the most notable being agranulocytosis. In recent years, however, mandatory blood monitoring has significantly reduced both the incidence of agranulocytosis and its associated mortality. The occurrence of seizures appears to be dose-related and can generally be managed by reduction in clozapine dosage. Less serious and more common side effects of clozapine including sedation, hypersalivation, tachycardia, hypotension, hypertension, weight gain, constipation, urinary incontinence, and fever can often be managed medically and are generally tolerated by the patient. Appropriate management of clozapine side effects facilitates a maximization of the benefits of clozapine treatment, and physicians and patients alike should be aware that there is a range of benefits to clozapine use that is wider than its risks.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10811238

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  32 in total

1.  Simultaneous side effects of both clozapine and valproate.

Authors:  J Nicolai; S J Smith; R W Keunen
Journal:  Intensive Care Med       Date:  2001-05       Impact factor: 17.440

Review 2.  The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.

Authors:  Corinne Beinat; Samuel D Banister; Marco Herrera; Vivian Law; Michael Kassiou
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

3.  Augmentation of olanzapine in treatment-resistant schizophrenia.

Authors:  Mathias Zink
Journal:  J Psychiatry Neurosci       Date:  2005-11       Impact factor: 6.186

4.  Management of clozapine-induced fever: a case of continued therapy throughout fever.

Authors:  Nicole Martin; Richard Williams
Journal:  J Psychiatry Neurosci       Date:  2013-07       Impact factor: 6.186

5.  ADN-1184 a monoaminergic ligand with 5-HT(6/7) receptor antagonist activity: pharmacological profile and potential therapeutic utility.

Authors:  M Kołaczkowski; P Mierzejewski; P Bieńkowski; A Wesołowska; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 6.  Restarting clozapine after neutropenia: evaluating the possibilities and practicalities.

Authors:  Eromona Whiskey; David Taylor
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 7.  [Augmenting atypical antipsychotic medications with clozapin].

Authors:  M Zink; H Dressing
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

Review 8.  [Pharmacological strategies for clozapine-induced hypersalivation: treatment with botulinum toxin B in one patient and review of the literature].

Authors:  K G Kahl; P Trillenberg; A Kordon; R Lencer; C Klein; J Hagenah
Journal:  Nervenarzt       Date:  2005-02       Impact factor: 1.214

9.  An initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients.

Authors:  Daniel J Abrams; Lijun Zheng; Kevin S Choo; Jun J Yang; Wei Wei; Thomas J Anchordoquy; Nasser H Zawia; Karen E Stevens
Journal:  Schizophr Res       Date:  2008-01-07       Impact factor: 4.939

10.  Clozapine-related EEG changes and seizures: dose and plasma-level relationships.

Authors:  Seema Varma; Delia Bishara; Frank M C Besag; David Taylor
Journal:  Ther Adv Psychopharmacol       Date:  2011-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.